Anticoagulation in preterm and term neonates: Why are they special?
Anticoagulation
Neonate
Pediatrics
Preterm
Thrombosis
Journal
Thrombosis research
ISSN: 1879-2472
Titre abrégé: Thromb Res
Pays: United States
ID NLM: 0326377
Informations de publication
Date de publication:
03 2020
03 2020
Historique:
received:
21
10
2019
revised:
20
12
2019
accepted:
23
12
2019
pubmed:
27
1
2020
medline:
22
6
2021
entrez:
27
1
2020
Statut:
ppublish
Résumé
The preterm and term neonatal population is most at risk for thrombotic complications in pediatrics. Among various treatment modalities, anticoagulation is primarily used in the management of thrombosis. Developmental differences in preterm and term infants compared to older infants and children and limitations of anticoagulation agents currently used are important considerations for treatment. Additionally, dosages and durations of anticoagulant treatment are widely variable across countries. This article will highlight the differences in anticoagulation in neonates compared to other populations due to developmental hemostatic changes, epidemiology of neonatal thrombosis, pharmacokinetic and pharmacodynamic properties of drugs used and presence of neonatal co-morbidities.
Identifiants
pubmed: 31982841
pii: S0049-3848(19)30552-3
doi: 10.1016/j.thromres.2019.12.019
pii:
doi:
Substances chimiques
Anticoagulants
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
113-121Informations de copyright
Copyright © 2020 Elsevier Ltd. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of competing interest No conflict of interest.